Skip to main content
Allergan's US dermatology portfolio sold to Almirall
8/3/2018

Allergan's US dermatology portfolio -- which includes acne treatments Aczone, or dapsone, Azelex, or azelaic acid, and Tazorac, or tazarotene, plus dermatosis drug Cordran tape, or fludroxycortide, and acne vulgaris drug Seysara, or sarecycline -- was purchased by Spain's Almirall. The deal gives Allergan a $550 million upfront payment and up to $100 million based on portfolio earnings.

Full Story: